Entrada Therapeutics Receives UK Authorization to Begin ELEVATE-44-201
ELEVATE-44-201, a Phase 1/2 multiple ascending dose (MAD) clinical study of ENTR-601-44, was authorized by the UK's Medicines and Healthcare Products Regulatory Agency (MHRA)...
Sidra Medicine Establishes Gene Therapy Center for Rare Genetic Diseases in Qatar
The announcement was made at Arab Health 2025, where Sidra Medicine will showcase its global patient care initiatives, including flagship services like the Heart...
In Brazil, the Government is Expected to Implement a Risk-Sharing Model with Roche for ELEVIDYS
Elevidys, a treatment for Duchenne muscular dystrophy, is the most costly medication authorized in Brazil and among the most expensive in the world, with...
Will Genethon and Eukarÿs Partnership Reduce the Cost of Gene Therapies?
The FDA-approved only gene therapy for Duchenne muscular dystrophy is costing far too much for families to afford. Families simply cannot afford this prohibitive...
Belief BioMed Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate BBM-D101
Belief BioMed Reports FDA IND Clearance for Gene Therapy Candidate BBM-D101 for Duchenne Muscular Dystrophy.
The U.S. Food and Drug Administration (FDA) has approved an...